

A sulfated glycosaminoglycan linkage
region is a novel type of Human Natural
Killer-1 (HNK-1) epitope expressed on
aggrecan in perineuronal nets

(ペリニューロナルネットを構成するアグリカン上には
新規 HNK-1 糖鎖が存在する)

藪野 景子

A sulfated glycosaminoglycan linkage region is a novel type of Human
Natural Killer-1 (HNK-1) epitope expressed on aggrecan in perineuronal
nets

Short title: A linkage type of HNK-1 epitope on aggrecan

Keiko Yabuno¹, Jyoji Morise¹, Yasuhiko Kizuka^{2, #a}, Noritaka Hashii³, Nana Kawasaki³,
Satoru Takahashi⁴, Shinji Miyata⁵, Tomomi Izumikawa⁵, Hiroshi Kitagawa⁵, Hiromu
Takematsu¹, and Shogo Oka^{1, *}

¹ Department of Biological Chemistry, Human Health Sciences, Graduate School of
Medicine, Kyoto University, Kyoto 606-8507, Japan.

² Department of Biological Chemistry, Graduate School of Pharmaceutical Sciences,
Kyoto University, Kyoto 606-8501, Japan.

³ Division of Biological Chemistry and Biologicals, National Institute of Health
Sciences, Tokyo 158-8501, Japan.

⁴ Department of Anatomy and Embryology Faculty of Medicine University of Tsukuba,

Tsukuba 305-8575, Japan.

⁵ Department of Biochemistry, Kobe Pharmaceutical University, Kobe 658-8558,

Japan.

* Corresponding Author

E-mail: shogo@hs.med.kyoto-u.ac.jp

^{#a} Present address: Disease Glycomics Team, RIKEN-Max Planck Joint Research

Center, Global Research Cluster, RIKEN, Wako 351-0198, Japan.

Abstract

Human natural killer-1 (HNK-1) carbohydrate (HSO₃-3GlcAβ1-3Galβ1-4GlcNAc-R) is highly expressed in the brain and required for learning and neural plasticity. We previously demonstrated that expression of the HNK-1 epitope is mostly abolished in knockout mice for GlcAT-P (*B3gat1*), a major glucuronyltransferase required for HNK-1 biosynthesis, but remained in specific regions such as perineuronal nets (PNNs) in these mutant mice. Considering PNNs are mainly composed of chondroitin sulfate proteoglycans (CSPGs) and regulate neural plasticity, GlcAT-P-independent expression of HNK-1 in PNNs is suggested to play a role in neural plasticity. However, the function, structure, carrier glycoprotein and biosynthetic pathway for GlcAT-P-irrelevant HNK-1 epitope remain unclear. In this study, we identified a unique HNK-1 structure on aggrecan in PNNs. To determine the biosynthetic pathway for the novel HNK-1, we generated knockout mice for GlcAT-S (*B3gat2*), the other glucuronyltransferase required for HNK-1 biosynthesis. However, GlcAT-P and GlcAT-S double-knockout mice did not exhibit reduced HNK-1 expression compared with single GlcAT-P-knockout mice, indicating an unusual

45 biosynthetic pathway for the HNK-1 epitope in PNNs. Aggrecan was purified from
46 cultured cells in which GlcAT-P and -S are not expressed and we determined the
47 structure of the novel HNK-1 epitope using liquid chromatography/mass spectrometry
48 (LC/MS) as a sulfated linkage region of glycosaminoglycans (GAGs),
49 HSO₃-GlcA-Gal-Gal-Xyl-R. Taken together, we propose a hypothetical model where
50 GlcAT-I, the sole glucuronyltransferase required for synthesis of the GAG linkage, is
51 also responsible for biosynthesis of the novel HNK-1 on aggrecan. These results could
52 lead to discovery of new roles of the HNK-1 epitope in neural plasticity.

Introduction

The extracellular matrix (ECM) plays vital roles in various physiological phenomena occurring in the central nervous system (CNS) [1-4]. In particular, perineuronal nets (PNNs), a specialized ECM structure surrounding neuronal cell bodies and proximal dendrites in the CNS, regulate neural plasticity [5, 6]. PNNs are composed of hyaluronan, chondroitin sulfate proteoglycans (CSPGs), link protein and tenascin-R [5-9] and ensheath parvalbumin (PV)-positive gamma-aminobutyric acid (GABA)-ergic interneurons and some pyramidal neurons [10-14]. Timing of PNN formation corresponds to the end of the critical period during which synaptogenesis, synaptic refinement and maturation of the nervous system occur [15-18], suggesting that formation of PNNs depends on completion or fixation of plastic change in neural activity. Previous reports demonstrated that cats reared in the dark with less sensory input showed delay in both the closure of the critical period and the emergence of PNNs in their brains [19, 20]. Additionally, sensory deprivation of whisker or facial vibrissae reduced the number of PNNs in rodent somatosensory cortex [21, 22]. These

data strongly suggest that activity-dependent formation of PNNs has an important role in the regulation of neural plasticity.

Digestion of the chondroitin sulfate (CS) chain on CSPGs, a major component of PNNs, resulted in the reactivation of ocular dominance plasticity in adult mice [16]. Additionally, transgenic mice overexpressing chondroitin 6-sulfotransferase-1 (C6ST-1), a sulfotransferase involved in the 6-*O*-sulfation of GalNAc residues of the repeating disaccharide units in the CS chain, exhibited persistent ocular dominant plasticity in the adult brain, probably due to abnormal PNN morphology [23]. These data indicate that CSPGs, especially their CS chains, critically regulate neural plasticity in PNNs, but the detailed molecular mechanisms underlying the CS-dependent neural plasticity remain unclear.

To visualize PNNs, several monoclonal antibodies have been used; e.g., human natural killer-1 (HNK-1), 4F4 [24], VC1.1 [25] and Cat-315 [26], all of which react with the HNK-1 carbohydrate epitope, suggesting that the HNK-1 carbohydrate is involved in neural plasticity as a PNN component. The HNK-1 epitope is highly expressed in the CNS and its unique structure was determined to be a sulfated

trisaccharide, HSO₃-3GlcAβ1-3Galβ1-4GlcNAc-R [27]. We cloned and characterized two glucuronyltransferases (GlcAT-P and GlcAT-S) and a sulfotransferase (HNK-1ST) as key enzymes responsible for HNK-1 biosynthesis [28-30]. We also demonstrated that GlcAT-P-knockout (PKO) mice show a significant decrease in the HNK-1 epitope, resulting in reduced long-term potentiation (LTP) at the hippocampal CA1 region and impaired spatial learning [31]. These phenotypes are likely due to impairments in spine maturation and in cell surface retention of glutamate receptors in developing brains [32], indicating that the HNK-1 carbohydrate synthesized by GlcAT-P is required for the proper function of the mammalian CNS. Although HNK-1 monoclonal antibody (mAb) immunoreactivity was mostly abolished in the PKO mouse brain, some HNK-1 epitopes remained in the PNNs that co-localized with the lectin *Wisteria floribunda agglutinin* (WFA), another well-established PNN marker [31]. These results suggest that the HNK-1 epitope expressed in PNNs is synthesized by another glucuronyltransferase involved in neural plasticity such as GlcAT-S; however, its function, carrier protein and structure remain unclear.

In this study, we first explored a carrier protein of the GlcAT-P-irrelevant HNK-1

100 in PNNs and identified aggrecan. To examine its biosynthetic pathway, we generated
101 GlcAT-S-knockout (SKO) mice as well as GlcAT-P and GlcAT-S double-knockout
102 (DKO) mice and revealed that GlcAT-S is not responsible for its biosynthesis.
103 Furthermore, using liquid chromatography/mass spectrometry (LC/MS) analysis, we
104 found that a unique linkage region of the HNK-1 structure
105 (HSO₃-GlcA-Gal-Gal-Xyl-R) is expressed on aggrecan, which is likely synthesized by
106 GlcAT-I but not by GlcAT-P and -S. Our study highlights new aspects of the HNK-1
107 epitope in PNNs.

Materials and Methods

Protein extraction from mouse brains

All the animal experiments were conducted according to the Fundamental Guidelines for Proper Conduct of Animal Experiments and Related Activities in Academic Research Institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology of Japan and approved by the Committees on Animal Experimentation of University of Tsukuba and Kyoto University. Whole brains dissected from 2- or 6-week-old mice were homogenized with 4 volumes of homogenizing buffer (20 mM Tris-HCl (pH 7.4) containing 150 mM NaCl, 1 mM EDTA and protease inhibitors (Nacalai Tesque)). The homogenates were centrifuged at $1,000 \times g$ for 10 min to remove nuclei, followed by centrifugation at $105,000 \times g$ for 60 min. The supernatants produced the Tris-buffered saline (TBS) soluble fractions. The pellets were rehomogenized with urea-containing buffer (10 mM Tris-HCl (pH7.4) containing 1 mM EDTA and 6 M urea) and then the homogenates were centrifuged at $105,000 \times g$ for 60 min. The resulting supernatants were the urea-soluble fractions. The urea- and TBS-soluble fractions were combined and used as soluble

fractions.

Glycosidase digestion

Soluble fraction proteins (30 µg) from mouse brains were precipitated with ethanol and suspended with 20 to 50 µl of chondroitinase buffer (10 mM Tris-HCl (pH7.4), 30 mM sodium acetate, 50 mM EDTA and protease inhibitors), followed by incubation with a final concentration of 250 µU/ml of chondroitinase ABC (chABC) (Seikagaku Corporation) for 3 h at 37°C. The reaction mixtures were denatured with 0.5% sodium dodecyl sulfate (SDS) for 5 min at 100°C. To reduce the SDS concentration, the solution was diluted with 4 volumes of phosphate-buffered saline (PBS) containing 25 mM EDTA, 1.25% NP-40 and 1.25% 2-mercaptoethanol. Peptide *N*-glycosidase F (PNGase F, Roche Applied Science) was added at the final concentration of 20 mU/µl, followed by incubation for 16 h at 37°C.

SDS-PAGE and western blotting

Proteins were separated in 3-10% gradient or 7% polyacrylamide gels and

transferred to nitrocellulose membranes. After blocking with 5% nonfat dry milk in PBS containing 0.05% Tween 20, the membranes were incubated with primary antibodies, followed by horseradish peroxidase (HRP)-conjugated secondary antibodies. Protein bands were detected using Super Signal West Pico chemiluminescence reagent (Thermo Fisher Scientific), and the signal intensities were quantified using Image Gauge software (FUJIFILM). The following primary antibodies were used: HNK-1 monoclonal antibody (mAb) (a hybridoma cell line purchased from American Type Culture Collection, final concentration 4 µg/ml), M6749 mAb (kindly provided by Dr. H. Tanaka, Kumamoto University, final concentration 4 µg/ml), 6B4 mAb (developed as described previously [33], final concentration 4 µg/ml), Cat-315 mAb (Millipore, 1:500), anti-aggrecan polyclonal antibody (pAb) (Millipore, 1:500), anti-phosphacan pAb (antiserum was raised in rabbits against recombinant full-length phosphacan, which was expressed in and purified from COS-1 cells, final concentration 3.4 µg/ml), anti-NCAM mAb (kindly provided by Dr. K. Ono, Kyoto Prefectural University, clone H28, final concentration 0.7 µg/ml), anti-actin mAb (Millipore, 1:1000), anti-Fc pAb (Jackson

ImmunoResearch, 1:1000), CS56 mAb (Sigma, 1:250) and anti-chondroitin sulfate A mAb (Seikagaku Corporation, clone IIH6, 1:250).

Immunoprecipitation

Soluble fractions (600 µg) from mouse brains (PKO and DKO) were dialyzed against TBS using Slide-A-Lyzer Dialysis Cassette (Thermo Fisher Scientific) or precipitated with ethanol. After dialysis or ethanol-precipitation, proteins were suspended with 50 µl of chondroitinase buffer, followed by incubation with a final concentration of 250 µU/ml of chABC for 3 h at 37°C. The reaction mixtures were denatured with 0.5% SDS for 3 min at 100°C. To reduce the SDS concentration, the solution was diluted with 4 volumes of TBS containing 1% Triton X-100, followed by incubation with anti-aggrecan antibody (8 µg/ml final concentration), anti-phosphacan antibody (15 µg/ml final concentration) or normal rabbit IgG (Santa Cruz, 4 µg/ml final concentration) for 30 min at 4°C. The mixtures were then incubated with Protein G Sepharose (GE Healthcare) O/N at 4°C with gentle shaking. The beads were washed extensively with TBS containing 0.1% Triton X-100 and bound proteins were eluted

by boiling in Laemmli sample buffer.

Immunohistochemistry

Mice were deeply anesthetized and transcardially perfused with PBS and subsequently with PBS containing 4% paraformaldehyde. After cryoprotection with 30% sucrose, the tissues were sliced in 40- μ m-thick sections using a microtome. Free-floating sections were incubated with 5 μ g/ml primary antibodies (HNK-1 mAb, 6B4 mAb, Cat-315 mAb and aggrecan pAb) or biotinylated WFA lectin (Sigma, 1:400) diluted with PBS containing 3% bovine serum albumin for 2 h at room temperature, followed by incubation with Alexa Fluor conjugated secondary antibodies (Molecular Probes, 1:400) or Fluorescein AvidinD (VECTOR Laboratories, 1:400) for 1 h at room temperature. Sections were visualized under a Fluoview laser confocal microscope system, FV1000-D IX81 (Olympus).

GlcAT-P (*B3gat1*) and GlcAT-S (*B3gat2*) deficient mice

The method for generation of GlcAT-P gene (*B3gat1*)-deficient mice (PKO) was

described previously [31]. GlcAT-S (*B3gat2*) gene-deficient mice (SKO) were produced as follows: genomic clone λ 1011 harboring the exon1 of murine GlcAT-S, containing the initiation codon and transmembrane region was isolated from a murine 129/SvJ λ phage library [34]. Construction of the targeting vector is schematically represented in Fig 1A. A 5' fragment (5.7 kb) containing a part of exon1 and 5'-end region and isolated by digestion using XbaI and BamHI was subcloned into pBluescript II SK(+) (pBS). A 3' fragment (1.1 kb), a portion of the intron between exon1 and exon2, was digested with SpeI and HindIII, rendered blunt using Klenow enzyme and cloned into the EcoRV site of pBS. pCH110 (a gift from Dr. M. Asano, Kanazawa University) was digested with HindIII and BamHI and the β -galactosidase gene (3.7-kb fragment released) was religated with the vector containing the 5' fragment. The neomycin resistance gene cassette in the vector pPGKneobpA [35] and the diphtheria toxin A (DT-A) gene cassette in vector pMC1DT-A [36] were introduced into the vector containing the 3' fragment as positive and negative selection makers, respectively. The resulting plasmid was digested with NotI and ApaI, religated with the vector containing the 5' fragment and β -galactosidase. The constructed

targeting vector was transfected into ES cells and positive selection was performed using G418 (GIBCO). ES clones possessing the targeting allele from homologous recombination were selected using PCR and genome DNA was isolated from positive clones and analyzed using Southern blotting (Fig 1B). Targeting cell clones were injected into C57BL/6 blastocysts to obtain chimeric mice.

Fig 1. Generation of GlcAT-S-deficient mice.

(A) Schematic diagram of the targeting construct. For targeted disruption of the mouse GlcAT-S gene (*B3gat2*), exon1 containing the initiation codon and transmembrane region were replaced with a neo/lacZ cassette. Hatched lines represent the fragments used for the construction of the targeting vector. PCR primers used for screening are shown in arrowheads. Black bars indicate probes for Southern blot analysis. (B) Southern blot analysis of targeted ES cell clones. Genomic DNA isolated from ES cell clones were digested with PstI or SpeI and EcoRV, blotted and then hybridized with the 3' or 5' probe, respectively. The expected sizes of the WT allele and targeted allele (KO) are indicated. The ES clones, 6, 29, 37, 62, 116, 127, 203 and 258 were positive

when screening using PCR. ES clone 115 was used as a negative control. (C) Western blot analysis of SKO mice. The membrane proteins were prepared from 6-week-old mouse kidneys (WT; +/+, heterozygote; +/-, homozygote; -/-). A non-sulfated form of HNK-1 epitope was detected with M6749 mAb.

Protein extraction from mouse kidney

Kidneys from 6-week-old wild-type (WT), GlcAT-S hetero (+/-) and homo (-/-) knockout mice were homogenized in 9 volumes of 20 mM Tris-HCl (pH 7.5) containing 150 mM NaCl, 1 mM EDTA and protease inhibitors at 4°C. The homogenates were centrifuged at $1,000 \times g$ for 10 min at 4°C to remove nuclei. The supernatants were centrifuged at $105,000 \times g$ for 1 h at 4°C. The resulting precipitates were used as membrane fractions.

cDNA construction

Expression plasmid of aggrecan-Fc was constructed as follows. Two separate PCR reactions were performed to generate two overlapping gene fragments predicted

236 to encode signal peptide, G1, CS2 and G3 domains (mini aggrecan) using human
237 aggrecan cDNA obtained from the DNAFORM as a template. In the first PCR, the
238 cDNA fragment containing signal peptide and G1 domain was amplified using a
239 5'-primer (5'- CGGGATCCGTCCAACCTCTTCAAGGTGAACT-3') containing an
240 in-frame BamHI site (underlined) and a 3'-primer
241 (5'-AAAGTCAGGCAGGCCTGTGTAGCAGATGGC-3'). In the second round of
242 PCR, the cDNA fragment containing CS2 and G3 domains was amplified using a
243 5'-primer (5'-GCCATCTGCTACACAGGCCTGCCTGACTTT-3') and a 3'-primer
244 (5'-CGGGATCCGTGGGCTGTGCTGGGGCGGCT-3') containing an in-frame
245 BamHI site (underlined). The two PCR products were gel-purified and used as a
246 template for a third PCR reaction containing the 5'-primer (5'-
247 CGGGATCCGTCCAACCTCTTCAAGGTGAACT-3') containing an in-frame BamHI
248 site and the 3'-primer (5'-CGGGATCCGTGGGCTGTGCTGGGGCGGCT-3')
249 containing an in-frame BamHI site. The final PCR fragment was digested with BamHI
250 and ligated into pcDNA3.1-myc/His vector (Invitrogen) predigested with BamHI to
251 obtain pcDNA3.1/mini aggrecan. The subcloning of the mini aggrecan into pEF-Fc

mammalian expression vector was performed as follows: to insert a splicing donor signal, a cDNA fragment encoding a C-terminal region of aggrecan was amplified using PCR with a sense primer 5'-GCATCTAGAAATTGAGTCCTCAAG-3' (endogenous XbaI site, underlined) and an antisense primer 5'-CCGTCTAGAGGATCCACTCACCGTGGGCTGTGCTGGGGCGGCTCCT-3' (XbaI site, BamHI site and a splicing donor signal GTGAGT, underlined) using pcDNA3.1/mini aggrecan as a template. After digestion with XbaI, the product was ligated into pcDNA3.1/mini aggrecan previously digested with XbaI. Subsequently, the resultant plasmid was digested with BamHI and the aggrecan fragment was ligated into the pEF-Fc empty vector previously digested with BamHI. Expression plasmid of phosphacan-myc-Fc, myc-Fc-tagged full-length rat phosphacan, was described previously [37].

Cell culture and transfection

COS-1 cells were purchased from American Type Culture Collection (ATCC CRL-1650). COS-1 cells were maintained in Dulbecco's modified Eagle's medium

supplemented with 10% fetal bovine serum at 37°C until 50-70% confluency. For transfection, cells were plated on 175-cm² culture flasks. Cells were transfected with the expression plasmids using X-tremeGENE HP DNA Transfection Reagent (Roche Applied Science) according to the manufacturer's protocol. After 5-6 h of transfection, the culture medium was replaced with Ajinomoto serum-free Medium 104 (Ajinomoto). Cells were incubated for an additional 3 days to produce culture medium containing secreted proteins.

Purification of recombinant aggrecan-Fc

Recombinant aggrecan-Fc was purified from the culture medium using Protein G Sepharose and eluted with 50 mM diethylamine pH 11.5 containing 150 mM NaCl. The eluate was immediately neutralized with 0.5 M NaH₂PO₄.

Quantification of chondroitin sulfate

The purified recombinant aggrecan-Fc was subjected to gel filtration on a PD-10 column (GE Healthcare). The flow-through fractions were collected and digested with

5 mIU of chABC (Seikagaku Corporation) in 60 mM sodium acetate, 50 mM Tris-HCl (pH 8.0) for 12 h at 37°C. The digests were derivatized with a fluorophore, 2-aminobenzamide, and then analyzed by anion-exchange high-performance liquid chromatography (SLC-10A, Shimadzu) on a PA-03 column (YMC). Identification and quantification of the resulting disaccharides were achieved by comparison with chondroitin sulfate-derived authentic unsaturated disaccharides (Seikagaku Corporation), as described previously [38].

LC/MS glycan analysis

The purified recombinant aggrecan-Fc treated with chABC and PNGase F to remove chondroitin sulfate and *N*-glycans was precipitated with ethanol and then lyophilized. *O*-glycans were released by hydrazinolysis and pyridylaminated according to a procedure described previously [37]. PA-labeled *O*-linked glycans were separated on a graphitized carbon column (150 × 0.075 mm, 5 µm; Chemicals Evaluation and Research Institute) at a flow rate of 300 nl/min in a Paradigm MS4 HPLC system (Michrom BioResources). The mobile phases were 1 mM ammonium acetate

containing 2% acetonitrile (A buffer) and 1 mM ammonium acetate containing 80%
acetonitrile (B buffer). The glycans were eluted with a linear gradient of 2–65% of B
buffer for 50 min. MS was performed using an Orbitrap Elite Mass Spectrometer
(Thermo Fisher Scientific). The electrospray voltage for MS was -2.5 kV in the
negative ion mode and the collision energy was 25% for the MS/MS and MS/MS/MS
experiments. Mass spectra were acquired by selected ion monitoring (SIM) mode. The
resolution was 60,000 and the scan range was m/z 782.5-832.5.

Results

Aggrecan is an HNK-1 carrier protein in PKO mice

In PKO mouse brain, HNK-1 epitope was mostly abolished except for PNNs, indicating that it is suitable to analyze PKO mice to characterize HNK-1 carrier protein in PNNs. Previous reports demonstrated that HNK-1 epitope was expressed on aggrecan in the adult mouse brain [39] and especially in PNNs [26, 40]. Therefore, we examined whether the carrier protein of GlcAT-P-irrelevant HNK-1 epitope was also aggrecan or not.

To characterize the carrier protein of the HNK-1 epitope in PNNs in PKO mouse brain, brain soluble fractions including major PNN components were prepared from 2-week-old (PNN-unformed) and 6-week-old (PNN-formed) wild type (WT) and PKO mice (Fig 2A). Consistent with our previous report, all HNK-1 immunoreactive bands detected in WT mice had disappeared in 2-week-old PKO mice (Fig 2A, *HNK-1 panel*, *lanes 1 to 6*) [32, 37], indicating that GlcAT-P is dominant for HNK-1 synthesis in the developing brain. In contrast, after PNN formation was completed, a faint smear band over 250 kDa was detected with HNK-1 mAb in 6-week-old PKO mice (Fig 2A,

324 *HNK-1 panel, lane 10*). Previous reports for the developing mouse brain showed that
325 an HNK-1 carrying smear protein over 250 kDa was a CSPG, phosphacan, and was
326 converged after chABC treatment [37, 39, 40, 41] (Fig 2A, *HNK-1 panel, lane 2*). This
327 suggests the smear pattern of the band in the 6-week-old PKO mice was also derived
328 from large CS chains. The molecular weight of the HNK-1-positive band in
329 6-week-old PKO mice shifted down after the removal of the CS chain with chABC.
330 (Fig 2A, *HNK-1 panel, lane 11*), demonstrating the HNK-1 carrier protein in the
331 6-week-old PKO mice was a CSPG. In contrast to *N*-glycan-linked HNK-1 epitopes on
332 many other HNK-1 carrier proteins such as GluA2, tenascin-R, NCAM, P0 and MAG
333 in the CNS [32, 42, 43], removal of *N*-glycans with PNGase F did not reduce the
334 HNK-1 signal in 6-week-old PKO mice (Fig 2A, *HNK-1 panel, lane 12*). This suggests
335 that the HNK-1 epitope attached to the CSPG in 6-week-old PKO mice is present on a
336 unique core glycan structure. The HNK-1-carrying molecule in 6-week-old PKO mice
337 was also detected using two other HNK-1-recognizing antibodies, 6B4 and Cat-315
338 [26, 33, 37, 39, 40, 41] (Fig 2A, *6B4 and Cat-315 panels*), and the signals for this
339 protein in 6-week-old WT mice appeared to be stronger than those for the other

HNK-1-carrying molecules, which is consistent with the previous report by Dino et al. [39]. This indicates these two HNK-1-related mAbs react with HNK-1 epitopes with different specificities from HNK-1 mAb and prefer the unique HNK-1 epitope on CSPG.

Considering the molecular weights of the PNN component CSPGs (aggrecan, phosphacan, versican, brevican and neurocan) [5-9], aggrecan and phosphacan were the most feasible HNK-1 carrier candidates in the 6-week-old PKO mice. To test this possibility, mouse brain soluble fractions were immunoblotted for phosphacan and aggrecan after chABC and PNGase F treatment (Fig 2B). The molecular weight of aggrecan was similar to that of HNK-1, which was minimally affected by digestion with PNGase F in 6-week-old PKO mice (Fig 2B, *aggrecan panel, lane 12 and HNK-1 panel*). In contrast, the molecular weight of phosphacan and its larger downshift after PNGase F digestion were different from HNK-1 (Fig 2B, *phosphacan panel, lane 12*). These results indicate that aggrecan is the HNK-1 carrier protein in the 6-week-old PKO mouse brains.

To further confirm this assumption, we immunoprecipitated aggrecan from brain

urea soluble fractions of 6-week-old PKO mice and then immunoblotted the precipitated aggrecan using HNK-1, 6B4, Cat-315 and anti-aggrecan antibodies. All three HNK-1 recognizing mAbs reacted with immunoprecipitated aggrecan; slightly higher reactivity with 6B4 and Cat-315 than HNK-1 mAb (Fig 2C) was observed, which was similar to the PKO soluble fraction (Fig 2A). Based on these results and the findings from other groups [26, 39, 40], in the 6-week-old mouse brain, we concluded that aggrecan was the carrier CSPG for the unique type of HNK-1 epitope generated in a GlcAT-P-independent manner.

Fig 2. HNK-1 carbohydrate epitope expressed in GlcAT-P-deficient mice.

(A, B) Soluble fractions prepared from 2- and 6-week-old mouse brains (WT and GlcAT-P-deficient mice) were treated with chABC with or without PNGase F, subjected to SDS-PAGE and then blotted using anti-HNK-1 mAb, 6B4 mAb, Cat-315 mAb, phosphacan pAb and aggrecan pAb. To compare the molecular weight of HNK-1 immunoreactive band with aggrecan or phosphacan, an HNK-1 mAb blot of 6-week-old PKO mice treated with chABC and PNGase F is shown on the right of the

aggrecan panel. (C) Using urea-soluble fractions from 6-week-old PKO mouse brains (input), aggrecan was immunoprecipitated using aggrecan pAb (IP: aggrecan) or normal rabbit IgG (IP: IgG). The precipitated aggrecan was subjected to SDS-PAGE and western blotting with HNK-1, 6B4, Cat-315 and aggrecan antibodies.

A unique HNK-1 epitope on aggrecan is located in PNNs

Next, to examine whether the HNK-1 epitope on aggrecan was located in PNNs in mature PKO brains, 6-week-old mouse brain sections were immunostained using HNK-1, 6B4 or Cat-315 and anti-aggrecan antibodies. As we reported previously [31], PKO mice showed an overall reduced HNK-1 reactivity, but the HNK-1 signals in PNN-like pattern almost completely remained in the PKO brains (compare Fig 3A and D). The remaining HNK-1 epitope in the PKO brain was largely colocalized with aggrecan (Fig 3D-F) and high magnification showed the colocalization in a typical PNN pattern (Fig 3F, inset). Staining of PKO sections with 6B4 and Cat-315 mAbs also showed the similar overlapped signals with aggrecan in PNN patterns (Fig 3G-L). Furthermore, PNNs were clearly detected with 6B4 and Cat-315 mAbs compared with

HNK-1 mAb, even in WT mouse brain sections (Fig 3A-C), indicating that these two mAbs preferentially recognize the unique HNK-1 epitope in PNNs. Taken together, these results further confirmed that the HNK-1 epitope on aggrecan in PNNs is biosynthesized by an unknown pathway independent of GlcAT-P.

Fig 3. HNK-1 carbohydrate and aggrecan are expressed in the PNNs.

Sagittal sections of cerebral cortex from 6-week-old WT (A-C) and PKO mice (D-L) were singly (for WT) or doubly (for PKO) immunostained with HNK-1 mAb (A, D), 6B4 mAb (B, G), or Cat-315 mAb (C, J), and aggrecan pAb (E, H, K). F, I and L are overlaid images. High magnification images of HNK-1-, 6B4- or Cat-315- and aggrecan-positive PNNs are shown in the insets. Scale bars, 200 μ m (A-C), 100 μ m (D-L) and 20 μ m (insets).

HNK-1 epitope is synthesized by a novel glucuronyltransferase

Other than GlcAT-P, only one glucuronyltransferase, GlcAT-S, has been shown to biosynthesize the typical HNK-1 structure, HSO₃-3GlcA β 1-3Gal β 1-4GlcNAc-R

[29]. To investigate whether the HNK-1 epitope in PNNs is biosynthesized by GlcAT-S, we generated GlcAT-S gene-deficient (SKO) mice as described in **Materials and Methods**. Briefly, construction of the targeting vector is schematically represented in Fig 1A. Eight ES clones among 356 tested showed the desired homologous recombination (Fig 1B). Two lines of SKO mice were generated from two independent ES clones. The heterozygotes were further backcrossed with C57BL/6 mice for more than 10 generations. The SKO mice were viable and fertile and their brains showed no obvious abnormalities (data not shown). As we reported previously, GlcAT-S is expressed in mouse kidney and the brain and is responsible for the non-sulfated HNK-1 carbohydrate in the kidney [44]. These non-sulfated HNK-1 carbohydrates detected with M6749 mAb, disappeared in the SKO kidney (Fig 1C).

Next, the PKO and SKO mice were interbred to obtain double-knockout (DKO) mice. DKO mice were also viable and fertile. Brain soluble fractions from 6-week-old PKO and DKO mice were subjected to glycosidase digestion and western blot analyses. Reactivity with HNK-1 in DKO mice was not reduced compared with PKO mice (Fig 4A, *HNK-1 panel*). The molecular weight of the HNK-1 reactive band in DKO mice

was also consistent with aggrecan rather than phosphacan (Fig 4A, *aggrecan and phosphacan panels*). In addition, the reactive band was detected using 6B4 and Cat-315 mAbs in the DKO mice (Fig 4A, *6B4 and Cat-315 panels*); the DKO and PKO mice showed similar results. The effect of PNGase F digestion and the amounts of loaded proteins were confirmed by immunoreactive bands with H28 (anti-NCAM mAb) and anti-actin mAb, respectively (Fig 4A, *H28 and actin panels*). These results indicate that aggrecan is the HNK-1 carrier protein in the 6-week-old DKO mouse brain. To further confirm this assumption, we immunoprecipitated aggrecan and phosphacan from brain soluble fractions of 6-week-old DKO mice and then immunoblotted the precipitated aggrecan and phosphacan using HNK-1, anti-aggrecan and anti-phosphacan antibodies. HNK-1 reactivity was observed on immunoprecipitated aggrecan but not on phosphacan (Fig 4B). Double-staining of brain sections with HNK-1, 6B4 or Cat-315 mAb and WFA lectin also showed the remaining HNK-1 reactivity in the PNNs of DKO mice (Fig 4F-N), which was similar to PKO mice (Fig 3D, G, and J and Fig 4C-E). These results suggested a novel glucuronyltransferase, but neither GlcAT-P nor -S, was responsible for biosynthesis of

the HNK-1 epitope in PNNs.

Fig 4. HNK-1 carbohydrate expressed in PKO and DKO mice.

(A) Soluble fractions from 6-week-old GlcAT-P-deficient mice (PKO) and GlcAT-P and -S double deficient mice (DKO) were treated with chABC and PNGase F, subjected to SDS-PAGE and blotted using HNK-1 mAb, 6B4 mAb, Cat-315 mAb, aggrecan pAb, phosphacan pAb, H28 (NCAM mAb) or actin mAb. The effect of PNGase F treatment was confirmed by western blotting with H28 mAb. Actin was used as the loading control. (B) Using soluble fractions from 6-week-old DKO mouse brains (input), aggrecan and phosphacan were immunoprecipitated with aggrecan pAb (IP: aggrecan), normal rabbit IgG (IP: IgG) or phosphacan pAb (IP: phosphacan). The precipitated aggrecan and phosphacan were subjected to SDS-PAGE and western blotting with HNK-1, aggrecan and phosphacan antibodies. (C-N) Sagittal sections of cerebral cortex from 6-week-old PKO (C-E) and DKO mice (F-N) were double-immunostained with HNK-1 mAb, 6B4 mAb or Cat-315 mAb (*red*) and WFA lectin (*green*). Scale bar, 100 μ m.

HNK-1ST is involved in HNK-1 synthesis in COS-1 cells

A possible glucuronyltransferase for biosynthesis of the HNK-1 epitope in PNNs is GlcAT-I that biosynthesizes glycosaminoglycans (GAGs) but displays extremely high homology to GlcAT-P (42.7% identity) [45]. GlcAT-I is the sole enzyme responsible for GlcA transfer for biosynthesis of the core tetrasaccharide structure of GAG, GlcA β 1-3Gal β 1-3Gal β 1-4Xyl, the so-called linkage region [46, 47]. Previous reports showed that overexpression of GlcAT-I elicits HNK-1 immunoreactivity [46] and HNK-1ST can act on the GAG linkage to suppress GAG elongation of thrombomodulin [48]. Based on these results, we assumed that GlcAT-I, working with HNK-1ST, was the most feasible candidate for biosynthesis of the HNK-1 epitope on aggrecan in the PNNs. To confirm this assumption, Fc-tagged short-form aggrecan (Fig 5A) was transiently expressed with or without HNK-1ST in COS-1 cells in which endogenous GlcAT-I but neither GlcAT-P nor GlcAT-S was expressed. Aggrecan-Fc was purified using Protein G Sepharose from culture medium and subjected to western blot analysis. When aggrecan-Fc was expressed alone, aggrecan-Fc was detected with

anti-Fc antibody as a smear band over 300 kDa (Fig 5B *anti-Fc panel, lane 1*). When co-expressed with HNK-1ST, the level of the upper smear band of aggrecan-Fc was relatively reduced and instead a sharp lower band became prominent (Fig 5B, *anti-Fc panel, lane 3*). The upper smear band converged at the lower sharp band with chABC treatment (Fig 5B, *anti-Fc panel, lanes 2 and 4*), indicating the lower sharp band was a non-CS-bearing aggrecan. More importantly, the non-CS-bearing lower band was HNK-1-positive in an HNK-1ST dependent manner (Fig 5B, *HNK-1 panel, lane 3*). The reactivity with HNK-1 mAb was unaffected with PNGase F treatment (data not shown), which was consistent with the results in the PKO mouse brain (Fig 2). These results suggest the possibility that the unique HNK-1 epitope on aggrecan is synthesized by stepwise actions of GlcAT-I and HNK-1ST to create a unique sulfated type of GAG linkage region, HSO₃-GlcAβ1-3Galβ1-3Galβ1-4Xyl.

Notably, the relative increase in the level of the non-CS-bearing lower band of aggrecan with HNK-1ST expression in Fig 5B suggests the addition of the HNK-1 epitope on aggrecan downregulates its CS chain biosynthesis. This was also supported by weaker immunoreactivities with anti-CS antibodies of aggrecan (CS56 and IIH6) in

the presence of overexpressed HNK-1ST (Fig 5B, *CS56 and IHH6 panels, lanes 3*). Quantification of the signal intensities in these blots revealed that CS56- and IHH6-immunoreactive signals of aggrecan-Fc in the presence of HNK-1ST were reduced to 40% and 44%, respectively, compared to those in the absence of HNK-1ST. In addition, we carried out a quantitative analysis of CS side chains using high-performance liquid chromatography. Recombinant aggrecan-Fc was expressed with or without HNK-1ST in COS-1 cells and purified from culture media. CS chains were prepared from the recombinant aggrecan-Fc by chABC treatment, and the amount and composition of CS-derived disaccharides were analyzed. While the disaccharide unit composition was unaffected, the total amount of CS on the aggrecan-Fc was decreased in the presence of HNK-1ST and the quantity ratio (ST(+)/ST(-) ratio) was similar to the value in the western blot analysis (Table 1). These results suggest that the synthesis of the HNK-1 epitope on the GAG linkage region inhibits its CS polymerization.

As shown in Fig 4B, the HNK-1 epitope in PNNs was specifically expressed on aggrecan but not on phosphacan. To examine whether this specific HNK-1 expression

is also observed in COS-1 cells, phosphacan-myc-Fc and/or aggrecan-Fc were transiently expressed with HNK-1ST. As shown in Fig 5C, HNK-1 immunoreactivity was not detected on phosphacan-myc-Fc but on the aggrecan-Fc. This result implies that HNK-1ST preferentially recognizes aggrecan as an acceptor rather than phosphacan, but the mechanism underlying this protein-selective modification is unclear at present.

Fig 5. Expression of a novel HNK-1 epitope on aggrecan in COS-1 cells.

(A) Schematic diagram of the Fc-tagged short aggrecan used in this study. (B) Aggrecan-Fc with or without HNK-1ST was heterologously expressed into COS-1 cells. Aggrecan-Fc in the culture medium was purified using a Protein G Sepharose column and digested with 100 μ U/ml chABC and then blotted with anti-Fc pAb, HNK-1 mAb and anti-CS antibodies (CS56 and clone IIH6). (C) Aggrecan-Fc and/or phosphacan-myc-Fc were transiently expressed with HNK-1ST-EGFP into COS-1 cells. Aggrecan-Fc and phosphacan-myc-Fc in the culture medium were precipitated with ethanol and digested with 200 μ U/ml chABC, subjected to SDS-PAGE and then

blotted with anti-Fc pAb, HNK-1 mAb, aggrecan pAb and phosphacan pAb.

Table 1. Quantification of chondroitin sulfate on the purified recombinant aggrecan-Fc.

aggrecan-Fc	unsaturated disaccharide [pmol/ml]			
	Δ Di-0S	Δ Di-6S	Δ Di-4S	Total
HNK-1ST(-)	120.9	145.5	318.4	584.8
HNK-1ST(+)	51.5	65.3	132.8	249.6
ST(+) / ST(-) ratio (%)	43%	45%	42%	43%

The purified recombinant aggrecan-Fc expressed with or without HNK-1ST was digested with chABC. The digests were derivatized with a fluorophore, 2-aminobenzamide, and then analyzed by anion-exchange high-performance liquid chromatography. Each value was normalized by the amount of aggrecan-Fc. Δ Di-0S, $\Delta^{4,5}$ HexUA α 1-3GalNAc; Δ Di-6S, $\Delta^{4,5}$ HexUA α 1-3GalNAc (6-*O*-sulfate); Δ Di-4S, $\Delta^{4,5}$ HexUA α 1-3GalNAc (4-*O*-sulfate). The lowest row shows the quantity ratio of chondroitin sulfate on aggrecan-Fc with or without HNK-1ST expression.

Identification of the glycan structure of the HNK-1 epitope on aggrecan

To further confirm that the sulfated linkage region is synthesized on aggrecan, aggrecan-Fc was co-expressed with HNK-1ST and purified from COS-1 cells. HNK-1-positive aggrecan was treated with chABC and PNGase F and then released. *O*-glycans were PA-labeled and analyzed using LC/MSⁿ. Fig 6A upper panel shows the base peak chromatogram obtained using SIM (m/z 782.5-832.5) in the negative ion mode. The major precursor ions in the mass spectra were automatically subjected to data-dependent collision-induced dissociation-MS/MS and MS/MS/MS. The extracted ion chromatogram (EIC) from m/z 807.0 to 807.4 is shown in Fig 6A lower panel. The singly charged ion (m/z 807.2) corresponding to PA-labeled HSO₃-GlcA-Gal-Gal-Xyl was detected in Peak A of the EIC. In the MS/MS spectrum of this ion, the product ion at m/z 727.2 corresponded to [M-H-S]⁻ and the ion at m/z 254.9 corresponded to B₁⁻ (Fig 6B, *upper panel*). In the MS/MS/MS spectrum acquired from product ion (m/z 727.2) in the MS/MS spectrum, the ions at m/z 551.1, 389.1 and 227.1 corresponded to Y₃⁻, Y₂⁻ and Y₁⁻, respectively. The ions at m/z 499.2 and 337.0 corresponded to [B₃-S]⁻ and [B₂-S]⁻, respectively. These results indicated the sulfate group was attached to the HexA-Hex-Hex-Xyl and most likely to HexA. From these results, we concluded the

sulfated tetrasaccharide, HSO₃-GlcA-Gal-Gal-Xyl, was expressed on aggrecan-Fc, the probable HNK-1 epitope expressed on aggrecan in PNNs.

Fig 6. LC/MSⁿ structural analysis of HNK-1 epitope on aggrecan.

(A) PA-labeled *O*-linked glycans were prepared from aggrecan-Fc co-expressed with HNK-1ST in COS-1 cells. The base peak chromatogram of the glycans was obtained using selected ion monitoring (SIM) (*m/z* 782.5-832.5) in the negative ion mode (*upper panel*). An extracted ion chromatogram (EIC) of the ion at *m/z* 807.0-807.4 (*lower panel*). (B) MS/MS spectra (*upper panel*) of the ion [M-H]⁻ (*m/z* 807.2) detected in peak A and MS/MS/MS spectra (*lower panel*) of the predominant product ion (*m/z* 727.2) in the MS/MS. S, sulfate group; HexA, hexuronic acid; Hex, hexose; Xyl-PA, xylose labeled with 2-aminopyridine.

Discussion

In this study, by analyzing double knockout mice for GlcAT-P (*B3gat1*) and GlcAT-S (*B3gat2*) both of which are involved in the canonical HNK-1 biosynthesis, we demonstrated that a unique HNK-1 structure is expressed on aggrecan in PNNs. Using COS-1 cells in which neither GlcAT-P nor GlcAT-S is expressed, we identified the unique HNK-1 epitope as a sulfated type of GAG linkage region synthesized on aggrecan in an HNK-1ST dependent manner. Therefore, we named this structure a linkage type HNK-1 epitope to be distinguished from classical HNK-1. Furthermore, expression of such unique HNK-1 epitope on aggrecan suppresses its CS biosynthesis (Fig 7).

To date, the HNK-1 epitope has been shown to be expressed on *N*-linked glycans or *O*-mannosylated glycans in the CNS [32, 42, 43, 49] and 6B4 and Cat-315 mAbs, which are widely used to stain PNNs, were believed to recognize the *N*-linked or *O*-mannosylated types of HNK-1 epitopes [37, 39, 40, 41]. In the present study, we demonstrated that a third type of HNK-1 epitope is expressed on the GAG linkage region of aggrecan after formation of PNNs and 6B4 and Cat-315 mAbs have higher

specificity for that type of HNK-1 epitope (Fig 2). Considering the reactivity of these mAbs to *O*-mannosylated type of HNK-1 in the developing brain [37, 39, 40, 41] (Fig 2A), epitopes of 6B4 and Cat-315 mAbs are likely switched during development from *O*-mannosylated HNK-1 on phosphacan to the linkage region type of HNK-1 on aggrecan. Several antibodies recognize the HNK-1 epitope [24-26]; however, we suggest that 6B4 and Cat-315 are better probes than HNK-1 mAb to detect the linkage type HNK-1 epitope in PNNs (Fig 3A, B and C). Recently, the serum of peripheral neuropathy patients having 6B4 or Cat-315 type autoantibodies showed higher treatment resistance than patients with general type of HNK-1 autoantibodies [50]. Difference in specificity of HNK-1-related mAbs could be a good indicator for severity of demyelinating diseases.

PNNs are expressed around GABAergic interneurons, especially parvalbumin expressing cells [10, 11, 13]. GABAergic interneurons are highly heterogeneous [51]. For example, more than 20 classes of interneurons have been identified in the hippocampus and neocortex, each with distinctive spatial and temporal capabilities to influence cortical circuits [52, 53]. HNK-1 positive PNNs largely colocalized with

aggrecan or WFA but PNNs expressing aggrecan or WFA were not always HNK-1-positive (Figs 3D-L and 4C-N), indicating that expression of the linkage type HNK-1 epitope is distinctly regulated around a subset of neurons. In addition, the number of Cat-315-positive PNNs changes in an activity-dependent manner in the rat superior olivary complex and the mouse barrel cortex [21, 54], and 6B4 and Cat-315-positive PNNs were prominently reduced in the age-dependent neurodegeneration model mouse brain [55]. These findings suggest that the linkage type HNK-1 epitope in PNNs is functionally involved in neural plasticity. Therefore, to better understand the role of HNK-1 in PNNs, identifying the cell types among the GABAergic interneurons that express this epitope is important.

Our structural analysis suggests that GlcAT-I, the sole enzyme identified for synthesis of the GAG linkage region to date, might be involved in the linkage type HNK-1 epitope on aggrecan in PNNs. Previous findings showing overexpression of GlcAT-I evoked HNK-1 immunoreactivity [46] and the sulfated linkage region was detected in human urine [56, 57] further supports our hypothesis that GlcAT-I is the enzyme responsible for the synthesis of the unusual HNK-1 on aggrecan. However,

607 directly demonstrating its involvement is difficult because GlcAT-I (*B3gat3*)-knockout
608 mice show embryonic lethality at a very early stage [58]. In addition, it is also difficult
609 to demonstrate the contribution of GlcAT-I by its knockdown targeting to
610 PNN-forming interneurons because the HNK-1 epitope is expressed in a subpopulation
611 of PNN-forming interneurons, which would make it hard to distinguish the signal
612 reduction in HNK-1 by GlcAT-I silencing from the original feature as a
613 non-HNK-1-expressing PNN.

614 We also demonstrated that heterologous expression of HNK-1ST is required for
615 synthesis of the linkage type HNK-1 epitope. Recently, it was shown that HNK-1ST
616 can transfer a sulfate group to steroid hormones to regulate estrogen signaling [59].
617 Furthermore, we reported that HNK-1ST negatively regulates biosynthesis of
618 *O*-mannosylated laminin-binding glycan essential for muscular functions [60]. These
619 results indicate that HNK-1ST is a versatile enzyme and transfers a sulfate group to
620 more substrates than expected.

621 We showed that HNK-1ST suppressed CS biosynthesis by synthesizing a HNK-1
622 epitope on the linkage region of aggrecan (Fig 5B and Table 1). Considering the

importance of the CS chain or its degree of sulfation for neural plasticity such as ocular dominance plasticity [16, 23, 61, 62], the linkage type HNK-1 epitope may indirectly regulate neural plasticity by reducing the number of CS chains. In PNN-formed 6-week-old PKO or DKO mouse brains, even after the linkage type HNK-1 epitope was expressed, aggrecan still showed the smear band pattern, indicating that aggrecan possesses CS chains and simultaneously the linkage type HNK-1 epitope. These results suggest that a limited number of CS chain attachment sites (i.e., several specific sites) on aggrecan are sulfated and negatively regulated by HNK-1ST. A recent report showed that synthesis of the CS chain is regulated by phosphorylation of the Xyl residue in the linkage region [63], thus phosphorylation of Xyl may help HNK-1ST recognize a linkage region.

In conclusion, in the present study we discovered a new aspect of the HNK-1 epitope. These results shed light on the distinct *in vivo* roles of three homologous glucuronyltransferases (GlcAT-P, -S, -I) for HNK-1 synthesis. Further studies should aim to clarify how the linkage type HNK-1 epitope is involved in neural plasticity and GAG synthesis in PNNs in the brain.

639

640 **Fig 7. Biosynthetic model for HNK-1 epitope on aggrecan in PNNs.**

641 GlcAT-I is responsible for synthesis of a linkage region of GAG, which is usually
642 further elongated into a long GAG chain (e.g., CS chain). HNK-1ST transfers a sulfate
643 group to GlcA of the linkage region of aggrecan, which likely results in the expression
644 of the linkage type HNK-1 epitope, HSO₃-GlcA-Gal-Gal-Xyl, in PNNs. The
645 expression of the HNK-1 epitope on aggrecan suppresses the CS polymerization that
646 starts from GlcA of the linkage region.

647

648 **Acknowledgments**

649 We would like to thank Ms. Tomoko Ikeda and Saki Yamashita for technical
650 assistance.

651

652 **Author contributions**

653 Conceived and designed the experiments: KY YK SO. Performed the experiments: KY
654 JM SM TI. Analyzed the data: KY HK HT SO. Contributed reagents/materials/analysis
655 tools: NH NK ST. Wrote the manuscript: KY YK SO.

References

1. Berardi N, Pizzorusso T, Maffei L. Extracellular matrix and visual cortical plasticity: freeing the synapse. *Neuron*. 2004; 44: 905-908.
2. Dityatev A, Schachner M, Sonderegger P. The dual role of the extracellular matrix in synaptic plasticity and homeostasis. *Nat Rev Neurosci*. 2010; 11: 735-746.
3. Frischknecht R, Gundelfinger ED. The brain's extracellular matrix and its role in synaptic plasticity. *Adv Exp Med Biol*. 2012; 970: 153-171.
4. Soleman S, Filippov MA, Dityatev A, Fawcett JW. Targeting the neural extracellular matrix in neurological disorders. *Neuroscience*. 2013; 253: 194-213.
5. Frischknecht R, Seidenbecher CI. The crosstalk of hyaluronan-based extracellular matrix and synapses. *Neuron Glia Biol*. 2008; 4: 249-257.
6. Wang D, Fawcett J. The perineuronal net and the control of CNS plasticity. *Cell Tissue Res*. 2012; 349: 147-160.
7. Matsui F, Nishizuka M, Yasuda Y, Aono S, Watanabe E, Oohira A. Occurrence of a N-terminal proteolytic fragment of neurocan, not a C-terminal half, in a perineuronal net in the adult rat cerebrum. *Brain Res*. 1998; 790: 45-51.

- 672 8. Brückner G, Grosche J, Schmidt S, Härtig W, Margolis RU, Delpech B, et al.
673 Postnatal development of perineuronal nets in wild-type mice and in a mutant
674 deficient in tenascin-R. J Comp Neurol. 2000; 428: 616-629.
- 675 9. Carulli D, Rhodes KE, Brown DJ, Bonnert TP, Pollack SJ, Oliver K, et al.
676 Composition of perineuronal nets in the adult rat cerebellum and the cellular origin
677 of their components. J Comp Neurol. 2006; 494: 559-577.
- 678 10. Kosaka T, Heizmann CW. Selective staining of a population of
679 parvalbumin-containing GABAergic neurons in the rat cerebral cortex by lectins
680 with specific affinity for terminal *N*-acetylgalactosamine. Brain Res. 1989; 483:
681 158-163.
- 682 11. Wintergerst ES, Faissner A, Celio MR. The proteoglycan DSD-1-PG occurs in
683 perineuronal nets around parvalbumin-immunoreactive interneurons of the rat
684 cerebral cortex. Int J Dev Neurosci. 1996; 14: 249-255.
- 685 12. Ohyama J, Ojima H. Labeling of pyramidal and nonpyramidal neurons with lectin
686 *Vicia villosa* during postnatal development of the guinea pig. J Comp Neurol.
687 1997; 389: 453-468.

- 688 13. Morris NP, Henderson Z. Perineuronal nets ensheath fast spiking,
689 parvalbumin-immunoreactive neurons in the medial septum/diagonal band
690 complex. *Eur J Neurosci.* 2000; 12: 828-838.
- 691 14. Alpár A, Gärtner U, Härtig W, Brückner G. Distribution of pyramidal cells
692 associated with perineuronal nets in the neocortex of rat. *Brain Res.* 2006; 1120:
693 13-22.
- 694 15. Blue ME, Parnavelas JG. The formation and maturation of synapses in the visual
695 cortex of the rat. I. Qualitative analysis. *J Neurocytol.* 1983; 12: 599-616.
- 696 16. Pizzorusso T, Medini P, Berardi N, Chierzi S, Fawcett JW, Maffei L. Reactivation
697 of ocular dominance plasticity in the adult visual cortex. *Science.* 2002; 298:
698 1248-1251.
- 699 17. Carulli D, Rhodes KE, Fawcett JW. Upregulation of aggrecan, link protein 1, and
700 hyaluronan synthases during formation of perineuronal nets in the rat cerebellum. *J*
701 *Comp Neurol.* 2007; 501: 83-94.

- 702 18. Galtrey CM, Kwok JC, Carulli D, Rhodes KE, Fawcett JW. Distribution and
703 synthesis of extracellular matrix proteoglycans, hyaluronan, link proteins and
704 tenascin-R in the rat spinal cord. *Eur J Neurosci.* 2008; 27: 1373-1390.
- 705 19. Hockfield S, Kalb RG, Zaremba S, Fryer H. Expression of neural proteoglycans
706 correlates with the acquisition of mature neuronal properties in the mammalian
707 brain. *Cold Spring Harb Symp Quant Biol.* 1990; 55: 505-514.
- 708 20. Lander C, Kind P, Maleski M, Hockfield S. A family of activity-dependent
709 neuronal cell-surface chondroitin sulfate proteoglycans in cat visual cortex. *J*
710 *Neurosci.* 1997; 17: 1928-1939.
- 711 21. McRae PA, Rocco MM, Kelly G, Brumberg JC, Matthews RT. Sensory
712 deprivation alters aggrecan and perineuronal net expression in the mouse barrel
713 cortex. *J Neurosci.* 2007; 27: 5405-5413.
- 714 22. Nakamura M, Nakano K, Morita S, Nakashima T, Oohira A, Miyata S. Expression
715 of chondroitin sulfate proteoglycans in barrel field of mouse and rat somatosensory
716 cortex. *Brain Res.* 2009; 1252: 117-129.

- 717 23. Miyata S, Komatsu Y, Yoshimura Y, Taya C, Kitagawa H. Persistent cortical
718 plasticity by upregulation of chondroitin 6-sulfation. *Nat Neurosci.* 2012; 15:
719 414-422.
- 720 24. Yamamoto M, Marshall P, Hemmendinger LM, Boyer AB, Caviness VS Jr.
721 Distribution of glucuronic acid-and-sulfate-containing glycoproteins in the central
722 nervous system of the adult mouse. *Neurosci Res.* 1988; 5: 273-298.
- 723 25. Celio MR, Blümcke I. Perineuronal nets--a specialized form of extracellular matrix
724 in the adult nervous system. *Brain Res Brain Res Rev.* 1994; 19: 128-145.
- 725 26. Matthews RT, Kelly GM, Zerillo CA, Gray G, Tiemeyer M, Hockfield S.
726 Aggreacan glycoforms contribute to the molecular heterogeneity of perineuronal
727 nets. *J Neurosci.* 2002; 22: 7536-7547.
- 728 27. Voshol H, van Zuylen CW, Orberger G, Vliegenthart JF, Schachner M. Structure
729 of the HNK-1 carbohydrate epitope on bovine peripheral myelin glycoprotein P0. *J*
730 *Biol Chem.* 1996; 271: 22957-22960.
- 731 28. Terayama K, Oka S, Seiki T, Miki Y, Nakamura A, Kozutsumi Y, et al. Cloning
732 and functional expression of a novel glucuronyltransferase involved in the

733 biosynthesis of the carbohydrate epitope HNK-1. *Proc Natl Acad Sci U S A*. 1997;
 734 94: 6093-6098.

735 29. Seiki T, Oka S, Terayama K, Imiya K, Kawasaki T. Molecular cloning and
 736 expression of a second glucuronyltransferase involved in the biosynthesis of the
 737 HNK-1 carbohydrate epitope. *Biochem Biophys Res Commun*. 1999; 255:
 738 182-187.

739 30. Bakker H, Friedmann I, Oka S, Kawasaki T, Nifant'ev N, Schachner M, et al.
 740 Expression cloning of a cDNA encoding a sulfotransferase involved in the
 741 biosynthesis of the HNK-1 carbohydrate epitope. *J Biol Chem*. 1997; 272,
 742 29942-29946.

743 31. Yamamoto S, Oka S, Inoue M, Shimuta M, Manabe T, Takahashi H, et al. Mice
 744 deficient in nervous system-specific carbohydrate epitope HNK-1 exhibit impaired
 745 synaptic plasticity and spatial learning. *J Biol Chem*. 2002; 277: 27227-27231.

746 32. Morita I, Kakuda S, Takeuchi Y, Itoh S, Kawasaki N, Kizuka Y, et al. HNK-1
 747 glyco-epitope regulates the stability of the glutamate receptor subunit GluR2 on
 748 the neuronal cell surface. *J Biol Chem*. 2009; 284: 30209-30217.

- 749 33. Maeda N, Matsui F, Oohira A. A chondroitin sulfate proteoglycan that is
750 developmentally regulated in the cerebellar mossy fiber system. Dev Biol. 1992;
751 151: 564-574.
- 752 34. Imiya K, Ishizaki T, Seiki T, Saito F, Inazawa J, Oka S, et al. cDNA cloning,
753 genomic structure and chromosomal mapping of the mouse
754 glucuronyltransferase-S involved in the biosynthesis of the HNK-1 carbohydrate
755 epitope. Gene. 2002; 296: 29-36.
- 756 35. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src
757 proto-oncogene leads to osteopetrosis in mice. Cell. 1991; 64: 693-702.
- 758 36. Yagi T, Nada S, Watanabe N, Tamemoto H, Kohmura N, Ikawa Y, et al. A novel
759 negative selection for homologous recombinants using diphtheria toxin A fragment
760 gene. Anal Biochem. 1993; 214: 77-86.
- 761 37. Morise J, Kizuka Y, Yabuno K, Tonoyama Y, Hashii N, Kawasaki N, et al.
762 Structural and biochemical characterization of *O*-mannose-linked human natural
763 killer-1 glycan expressed on phosphacan in developing mouse brains.
764 Glycobiology. 2014; 24: 314-324.

- 765 38. Kitagawa H, Kinoshita A, Sugahara, K. Microanalysis of
766 glycosaminoglycan-derived disaccharides labeled with the fluorophore
767 2-aminoacridone by capillary electrophoresis and high-performance liquid
768 chromatography. Anal Biochem. 1995; 232: 114-121.
- 769 39. Dino MR, Harroch S, Hochfield S, Matthews RT. Monoclonal antibody Cat-315
770 detects a glycoform of receptor protein tyrosine phosphatase beta/phosphacan early
771 in CNS development that localizes to extrasynaptic sites prior to synapse formation.
772 Neuroscience. 2006; 142: 1055-1069.
- 773 40. Dwyer CA, Baker E, Hu H, Matthews RT. RPTP ζ /phosphacan is abnormally
774 glycosylated in a model of muscle-eye-brain disease lacking functional POMGnT1.
775 Neuroscience. 2012; 220: 47-61.
- 776 41. Dwyer CA, Katoh T, Tiemeyer M, Matthews RT. Neurons and glia modify
777 RPTP ζ /phosphacan with cell-specific *O*-mannosyl glycans in the developing brain.
778 J Biol Chem. 2015; 290: 10256-10273.
- 779 42. Saghatelian AK, Gorissen S, Albert M, Hertlein B, Schachner M, Dityatev A. The
780 extracellular matrix molecule tenascin-R and its HNK-1 carbohydrate modulate

781 perisomatic inhibition and long-term potentiation in the CA1 region of the
 782 hippocampus. *Eur J Neurosci.* 2000; 12: 3331-3342.

783 43. Kleene R, Schachner M. Glycans and neural cell interactions. *Nat Rev Neurosci.*
 784 2004; 5: 195-208.

785 44. Tagawa H, Kizuka Y, Ikeda T, Itoh S, Kawasaki N, Kurihara H, et al. A
 786 non-sulfated form of the HNK-1 carbohydrate is expressed in mouse kidney. *J Biol*
 787 *Chem.* 2005; 280: 23876-23883.

788 45. Kitagawa H, Tone Y, Tamura J, Neumann KW, Ogawa T, Oka S, et al. Molecular
 789 cloning and expression of glucuronyltransferase I involved in the biosynthesis of
 790 the glycosaminoglycan-protein linkage region of proteoglycans. *J Biol Chem.*
 791 1998; 273: 6615-6618.

792 46. Tone Y, Kitagawa H, Imiya K, Oka S, Kawasaki T, Sugahara K. Characterization
 793 of recombinant human glucuronyltransferase I involved in the biosynthesis of the
 794 glycosaminoglycan-protein linkage region of proteoglycans. *FEBS Lett.* 1999;
 795 459: 415-420.

- 796 47. Tone Y, Pedersen LC, Yamamoto T, Izumikawa T, Kitagawa H, Nishihara J, et al.
797 2-*O*-phosphorylation of xylose and 6-*O*-sulfation of galactose in the protein
798 linkage region of glycosaminoglycans influence the glucuronyltransferase-I
799 activity involved in the linkage region synthesis. J Biol Chem. 2008; 283:
800 16801-16807.
- 801 48. Nakagawa N, Izumikawa T, Kitagawa H, Oka S. Sulfation of glucuronic acid in
802 the linkage tetrasaccharide by HNK-1 sulfotransferase is an inhibitory signal for
803 the expression of a chondroitin sulfate chain on thrombomodulin. Biochem
804 Biophys Res Commun. 2011; 415: 109-113.
- 805 49. Yuen CT, Chai W, Loveless RW, Lawson AM, Margolis RU, Feizi, T. Brain
806 contains HNK-1 immunoreactive *O*-glycans of the sulfoglucuronyl lactosamine
807 series that terminate in 2-linked or 2,6-linked hexose (mannose). J Biol Chem.
808 1997; 272, 8924-8931.
- 809 50. Hamada Y, Hirano M, Kuwahara M, Samukawa M, Takada K, Morise J, et al.
810 Binding specificity of anti-HNK-1 IgM M-protein in anti-MAG neuropathy:
811 Possible clinical relevance. Neurosci Res. 2015; 91: 63-68.

- 812 51. Bartolini G, Ciceri G, Marín O. Integration of GABAergic interneurons into
813 cortical cell assemblies: lessons from embryos and adults. *Neuron*. 2013; 79:
814 849-864.
- 815 52. Klausberger T, Somogyi P. Neuronal diversity and temporal dynamics: the unity of
816 hippocampal circuit operations. *Science*. 2008; 321: 53-57.
- 817 53. Fishell G, Rudy B. Mechanisms of inhibition within the telencephalon: "where the
818 wild things are". *Annu Rev Neurosci*. 2011; 34: 535-567.
- 819 54. Myers AK, Ray J, Kulesza RJ Jr. Neonatal conductive hearing loss disrupts the
820 development of the Cat-315 epitope on perineuronal nets in the rat superior olivary
821 complex. *Brain Res*. 2012; 1465: 34-47.
- 822 55. Saitoh Y, Matsui F, Chiba Y, Kawamura N, Keino H, Satoh M, et al. Reduced
823 expression of MAb6B4 epitopes on chondroitin sulfate proteoglycan aggrecan in
824 perineuronal nets from cerebral cortices of SAMP10 mice: a model for
825 age-dependent neurodegeneration. *J Neurosci Res*. 2008; 86: 1316-1323.
- 826 56. Wakabayashi H, Natsuka S, Mega T, Otsuki N, Isaji M, Naotsuka M, et al. Novel
827 proteoglycan linkage tetrasaccharides of human urinary soluble thrombomodulin,

828 SO₄-3GlcAβ1-3Galβ1-3(±Siaα2-6)Galβ1-4Xyl. J Biol Chem. 1999; 274:
829 5436-5442.

830 57. Hashiguchi T, Mizumoto S, Nishimura Y, Tamura J, Yamada S, Sugahara K.
831 Involvement of HNK-1 sulfotransferase in the biosynthesis of the GlcUA(3-*O*-
832 sulfate)-Gal-Gal-Xyl tetrasaccharide found in α-thrombomodulin from human
833 urine. J Biol Chem. 2011; 286: 33003-33011.

834 58. Izumikawa T, Kanagawa N, Watamoto Y, Okada M, Saeki M, Sakano M, et al.
835 Impairment of embryonic cell division and glycosaminoglycan biosynthesis in
836 glucuronyltransferase-I-deficient mice. J Biol Chem. 2010; 285: 12190-12196.

837 59. Suzuki-Anekoji M, Suzuki A, Wu SW, Angata K, Murai KK, Sugihara K, et al. In
838 vivo regulation of steroid hormones by the Chst10 sulfotransferase in mouse. J
839 Biol Chem. 2013; 288: 5007-5016.

840 60. Nakagawa N, Takematsu H, Oka S. HNK-1 sulfotransferase-dependent sulfation
841 regulating laminin-binding glycans occurs in the post-phosphoryl moiety on
842 α-dystroglycan. Glycobiology. 2013; 23: 1066-1074.

- 843 61. Galtrey CM, Fawcett JW. The role of chondroitin sulfate proteoglycans in
844 regeneration and plasticity in the central nervous system. *Brain Res Rev.* 2007; 54:
845 1-18.
- 846 62. Miyata S, Kitagawa H. Mechanisms for modulation of neural plasticity and axon
847 regeneration by chondroitin sulphate. *J Biochem.* 2015; 157: 13-22.
- 848 63. Izumikawa T, Sato B, Mikami T, Tamura J, Igarashi M, Kitagawa H.
849 GlcUA β 1-3Gal β 1-3Gal β 1-4Xyl(2-*O*-phosphate) is the preferred substrate for
850 chondroitin *N*-acetylgalactosaminyltransferase-1. *J Biol Chem.* 2015; 290:
851 5438-5448.